Pembrolizumab for Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...
Publications
2 shownPembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,145
- Institution
- Sheba Medical Center
External Links
Identifiers
- ORCID
- 0000-0001-9632-6686
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.